(-0.47%) 5 025.50 points
(-0.38%) 37 862 points
(-0.72%) 17 422 points
(0.58%) $83.21
(-0.80%) $1.743
(0.09%) $2 400.10
(0.09%) $28.41
(-0.64%) $948.40
(-0.05%) $0.939
(-0.06%) $11.03
(-0.05%) $0.804
(-0.58%) $93.36
Live Chart Being Loaded With Signals
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures...
Stats | |
---|---|
Today's Volume | 82 608.00 |
Average Volume | 3.75M |
Market Cap | 8.37B |
EPS | £0 ( 2024-02-27 ) |
Last Dividend | £18.38 ( 2023-03-30 ) |
Next Dividend | £0 ( N/A ) |
P/E | 39.88 |
ATR14 | £0.357 (0.04%) |
Volume Correlation
Smith & Nephew plc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Smith & Nephew plc Correlation - Currency/Commodity
Smith & Nephew plc Financials
Annual | 2023 |
Revenue: | £5.55B |
Gross Profit: | £3.82B (68.82 %) |
EPS: | £0.300 |
Q2 | 2023 |
Revenue: | £1.37B |
Gross Profit: | £949.00M (69.42 %) |
EPS: | £0.0985 |
Q1 | 2023 |
Revenue: | £1.37B |
Gross Profit: | £949.00M (69.42 %) |
EPS: | £0.0985 |
Q4 | 2022 |
Revenue: | £1.31B |
Gross Profit: | £934.00M (71.43 %) |
EPS: | £0.0262 |
Financial Reports:
No articles found.
Smith & Nephew plc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
£12.91 (N/A) |
£0 (N/A) |
£18.38 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
£0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | £3.45 | 1993-05-10 |
Last Dividend | £18.38 | 2023-03-30 |
Next Dividend | £0 | N/A |
Payout Date | 2023-05-17 | |
Next Payout Date | N/A | |
# dividends | 64 | -- |
Total Paid Out | £440.59 | -- |
Avg. Dividend % Per Year | 1.26% | -- |
Score | 3.51 | -- |
Div. Sustainability Score | 6.37 | |
Div.Growth Potential Score | 2.75 | |
Div. Directional Score | 4.56 | -- |
Year | Amount | Yield |
---|---|---|
1993 | £0 | 0.00% |
1994 | £0 | 0.00% |
1995 | £0 | 0.00% |
1996 | £0 | 0.00% |
1997 | £0 | 0.00% |
1998 | £0 | 0.00% |
1999 | £0 | 0.00% |
2000 | £0 | 0.00% |
2001 | £0 | 0.00% |
2002 | £0 | 0.00% |
2003 | £0 | 0.00% |
2004 | £0 | 0.00% |
2005 | £0 | 0.00% |
2006 | £0 | 0.00% |
2007 | £0 | 0.00% |
2008 | £0 | 0.00% |
2009 | £0 | 0.00% |
2010 | £0 | 0.00% |
2011 | £0 | 0.00% |
2012 | £0 | 0.00% |
2013 | £0 | 0.00% |
2014 | £0 | 0.00% |
2015 | £0 | 0.00% |
2016 | £0 | 0.00% |
2017 | £0 | 0.00% |
2018 | £26.91 | 1.93% |
2019 | £28.49 | 1.99% |
2020 | £29.73 | 1.62% |
2021 | £27.12 | 1.73% |
2022 | £31.31 | 2.40% |
2023 | £18.38 | 1.64% |
2024 | £0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
VMUK.L | Dividend Junior | 2023-05-18 | Annually | 7 | 1.91% | |
MWY.L | Dividend Knight | 2023-09-28 | Semi-Annually | 43 | 0.48% | |
ELCO.L | Dividend Knight | 2023-09-21 | Annually | 29 | 0.64% | |
SIHL.L | Dividend Junior | 2023-07-06 | Sporadic | 11 | 2.42% | |
JAGI.L | Dividend King | 2023-07-13 | Quarterly | 27 | 2.39% | |
BUR.L | Dividend Knight | 2023-11-09 | Annually | 14 | 0.70% | |
PCFT.L | Dividend Knight | 2023-08-03 | Semi-Annually | 11 | 1.80% | |
FRES.L | Dividend Knight | 2023-08-10 | Semi-Annually | 17 | 1.24% | |
AERI.L | Dividend Knight | 2023-08-17 | Quarterly | 6 | 2.80% | |
SUP.L | Dividend Knight | 2023-08-31 | Annually | 4 | 1.22% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0482 | 1.500 | 9.04 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0195 | 1.200 | 9.35 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0372 | 1.500 | -0.697 | -1.046 | [0.1 - 1] |
payoutRatioTTM | 1.351 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.775 | 0.800 | 6.13 | 4.90 | [1 - 3] |
quickRatioTTM | 0.103 | 0.800 | -4.10 | -3.28 | [0.8 - 2.5] |
cashRatioTTM | 0.133 | 1.500 | -0.372 | -0.558 | [0.2 - 2] |
debtRatioTTM | 0.309 | -1.500 | 4.85 | -7.28 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.279 | 2.00 | 9.91 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -0.0183 | 2.00 | -0.00916 | -0.0183 | [0 - 20] |
debtEquityRatioTTM | 0.591 | -1.500 | 7.64 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.701 | 1.000 | 1.655 | 1.655 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.120 | 1.000 | 9.59 | 9.59 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0790 | 1.000 | -0.672 | -0.672 | [0.2 - 2] |
assetTurnoverTTM | 0.405 | 0.800 | -0.635 | -0.508 | [0.5 - 2] |
Total Score | 6.37 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 54.56 | 1.000 | 4.59 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0372 | 2.50 | -0.448 | -1.046 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -0.0183 | 2.00 | -0.00611 | -0.0183 | [0 - 30] |
dividendYielPercentageTTM | 2.87 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.279 | 2.00 | 9.91 | 10.00 | [0 - 30] |
payoutRatioTTM | 1.351 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0602 | 1.000 | -0.994 | 0 | [0.1 - 0.5] |
Total Score | 2.75 |
Smith & Nephew plc
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators